Tyrosylleucine (YL), administered orally, intracerebroventricularly, or intraperitoneally exhibits a potent antidepressant-like activity in the forced swim and tail suspension tests in na ve mice[1].
| Animal Model: | Male ddY mice (24-27g)[1] |
| Dosage: | 0.1-30mg/kg, i.p.; 0.1-1.0 nmol/mouse, i.c.v.; 30-100mg/kg, p.o. |
| Administration: | Administered orally, intracerebroventricularly, or intraperitoneally |
| Result: | Decreased immobility time after intraperitoneal (1-30mg/kg) and intracerebroventricular (0.3-1 nmol/mouse) administrations in the FST.
Exhibited a potent antidepressant-like activity in the forced swim and tail suspension tests in nave mice.
|
